Apnimed

Apnimed to Present at the 32nd Annual Oppenheimer Healthcare Conference

Retrieved on: 
Thursday, March 10, 2022
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Hypertension, Sleep apnea, Twitter, Risk, OSA, Diabetes, Sleep, Quality of life, Obstructive sleep apnea, Oppenheimer Holdings, Oppenheimer, Patient, CPAP, Central nervous system, Stroke, Population, Cardiovascular disease, Relaxation, LinkedIn, Pharmaceutical industry, Apnimed, Obstructive Sleep Apnea, APNIMED, OBSTRUCTIVE SLEEP APNEA

Please contact your representative at Oppenheimer & Co. to schedule a virtual one-on-one meeting with Apnimed senior management during the conference.

Key Points: 
  • Please contact your representative at Oppenheimer & Co. to schedule a virtual one-on-one meeting with Apnimed senior management during the conference.
  • Apnimeds lead development program targets the neurologic control of upper airway muscles to maintain an open airway during sleep.
  • Based in Cambridge, Mass., the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders.
  • Sleep-related muscular relaxation driven by the central nervous system is the key neurologic mechanism that causes OSA.

Apnimed Study APC-004 Phase 2 Data to be Presented at World Sleep 2022

Retrieved on: 
Wednesday, March 9, 2022
General Health, Other Health, Health, Pharmaceutical, Clinical Trials, HB, Patient, OSA, Pharmaceutical industry, Medical imaging, Study APC-004, Obstructive Sleep Apnea, Apnimed, STUDY APC-004, OBSTRUCTIVE SLEEP APNEA, APNIMED

Study APC-004 ( clinicaltrials.gov identifier NCT04631107 ) was a randomized, double-blind, placebo-controlled, crossover design Phase 2 study of 32 patients who met eligibility criteria for mild to moderate OSA.

Key Points: 
  • Study APC-004 ( clinicaltrials.gov identifier NCT04631107 ) was a randomized, double-blind, placebo-controlled, crossover design Phase 2 study of 32 patients who met eligibility criteria for mild to moderate OSA.
  • The median HB for participants on placebo was significantly higher than for patients on the high dose (p
  • Apnimeds lead development program targets the neurologic control of upper airway muscles to maintain an open airway during sleep.
  • Based in Cambridge, Mass., the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders.

Apnimed Announces Dosing of First Patient in Phase 2 MARIPOSA Confirmatory Trial of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea (OSA)

Retrieved on: 
Thursday, December 16, 2021
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, LinkedIn, Hypertension, PROMIS, Patient-Reported Outcomes Measurement Information System, Sleep, Sleep apnea, Stroke, Population, Volunteering, AHI, Obstructive sleep apnea, Interest, Risk, Sleep disorder, Relaxation, Patient, Cardiovascular disease, Quality of life, Trazodone, NCE, Apnea–hypopnea index, Twitter, HB, CPAP, Diabetes, Central nervous system, Pharmaceutical industry, MARIPOSA, AD109, AD504, Obstructive Sleep Apnea, Apnimed, MARIPOSA, AD109, AD504, OBSTRUCTIVE SLEEP APNEA, APNIMED

MARIPOSA also incorporates a sub-study of AD504, a second investigational oral medication being developed by Apnimed as a potential treatment for OSA.

Key Points: 
  • MARIPOSA also incorporates a sub-study of AD504, a second investigational oral medication being developed by Apnimed as a potential treatment for OSA.
  • With the MARIPOSA study underway, we are one step closer to bringing patients a potential new oral treatment option for OSA.
  • Apnimed is a clinical-stage pharmaceutical company working to transform the treatment of sleep apnea based on a simple idea patients with obstructive sleep apnea will potentially benefit from treatment with a safe and effective oral medication.
  • Based in Cambridge, Massachusetts, the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders.

Apnimed Achieves Meaningful Results in Proof-of-Concept Crossover Study With Oral Therapeutic Candidates AD504 and AD182 for the Treatment of Obstructive Sleep Apnea

Retrieved on: 
Tuesday, November 16, 2021
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Heel, Trazodone, Hypopnea, HB, Sleep, Patient, Obstructive sleep apnea, AHI, Â, OSA, Pharmaceutical industry, AD504, Obstructive Sleep Apnea, Apnimed, AD504, OBSTRUCTIVE SLEEP APNEA, APNIMED

Additionally, the studys secondary endpoint was met with a significant reduction of sleep apnea specific hypoxic burden (HB) following treatment with AD504.

Key Points: 
  • Additionally, the studys secondary endpoint was met with a significant reduction of sleep apnea specific hypoxic burden (HB) following treatment with AD504.
  • Were pleased with the reduction in HB demonstrated by AD504 in this small, proof-of-concept, Phase 2 study, said Larry Miller, M.D., Chief Executive Officer of Apnimed.
  • Apnimed is a clinical-stage pharmaceutical company working to transform the treatment of sleep apnea based on a simple idea patients with obstructive sleep apnea will benefit from treatment with a safe and effective oral medication.
  • Based in Cambridge, Mass., the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders.

Apnimed Announces Positive Phase 2 (Study APC-003) Data Demonstrating Durability-of-Effect and Improved Quality-of-Life in Patients with Obstructive Sleep Apnea After Investigational AD109 Treatment

Retrieved on: 
Wednesday, October 13, 2021
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Apnea, Obstructive sleep apnea, Clinical trial, Sleep, Hypopnea, HB, Disease, AHI, Safety, Quality of Life Index for Atopic Dermatitis, Quality of life, Pharmaceutical industry, AD109, Obstructive Sleep Apnea, Apnimed, AD109, OBSTRUCTIVE SLEEP APNEA, APNIMED

Additionally, during the open-label extension phase of this clinical trial, AD109 was shown to have a durability-of-effect when patients took AD109 for 28 days.

Key Points: 
  • Additionally, during the open-label extension phase of this clinical trial, AD109 was shown to have a durability-of-effect when patients took AD109 for 28 days.
  • Patients also experienced improvements in quality-of-life, nighttime breathing, and sleep across both objective and subjective measures.
  • Apnimed is a clinical-stage pharmaceutical company working to transform the treatment of sleep apnea based on a simple idea patients with Obstructive Sleep Apnea will benefit from treatment with a safe and effective oral medication.
  • Based in Cambridge, Mass., the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders.

Apnimed to Present at the Canaccord Genuity 41st Annual Growth Conference

Retrieved on: 
Friday, August 6, 2021
Pharmaceutical, Health, Clinical Trials, Other Health, Sleep apnea, Disorder, Stroke, Population, Patient, Conference, CPAP, OSA, Diabetes, Relaxation, Central nervous system, Cardiovascular disease, Risk, Sleep, Hypertension, Quality of life, Obstructive sleep apnea, Canaccord Genuity, Pharmaceutical industry, Obstructive Sleep Apnea, Apnimed, OBSTRUCTIVE SLEEP APNEA, APNIMED

Apnimed, a clinical-stage pharmaceutical company focused on developing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that the Companys management team will participate in the Canaccord Genuity Virtual 41st Annual Growth Conference, held August 12-13, 2021.

Key Points: 
  • Apnimed, a clinical-stage pharmaceutical company focused on developing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that the Companys management team will participate in the Canaccord Genuity Virtual 41st Annual Growth Conference, held August 12-13, 2021.
  • Management will be available August 12-13 throughout the conference for virtual one-on-one.
  • Investors interested in arranging a meeting with the Companys management during the conference should contact the Canaccord Genuity conference coordinator.
  • Based in Cambridge, Mass., the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders.

David P. White, M.D. Appointed Senior Vice President of Medical Affairs at Apnimed

Retrieved on: 
Tuesday, July 27, 2021
Biotechnology, General Health, Medical devices, Health, Clinical trials, Sleep disorders, Branches of biology, Sleep apnea, Obstructive sleep apnea, Apnea, Sleep, Sleep medicine, International Classification of Sleep Disorders, Obstructive Sleep Apnea, Apnimed, OBSTRUCTIVE SLEEP APNEA, APNIMED

Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for obstructive sleep apnea and related disorders, today announced that David P. White, M.D., a world-renowned leader in sleep disorders has been appointed Senior Vice President of Medical Affairs.

Key Points: 
  • Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for obstructive sleep apnea and related disorders, today announced that David P. White, M.D., a world-renowned leader in sleep disorders has been appointed Senior Vice President of Medical Affairs.
  • Clinicians understand that obstructive sleep apnea is a prevalent and debilitating medical condition affecting the health and well-being of patients.
  • There is a tremendous unmet need for a safe, effective, and easy-to-use treatment option that addresses the underlying cause of the disease.
  • In addition to his new position at Apnimed, Dr. White is a Professor of Medicine, part-time, at Harvard Medical School in Boston, Mass.

Apnimed to Present at the Ladenburg Thalmann Virtual Healthcare Conference

Retrieved on: 
Tuesday, July 6, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Sleep disorders, Branches of biology, Clinical medicine, Obstructive sleep apnea, Sleep apnea, Osa, Apnea, Sleep medicine, Obstructive Sleep Apnea, Apnimed, OBSTRUCTIVE SLEEP APNEA, APNIMED

Apnimed, a clinical-stage pharmaceutical company focused on developing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that the Companys management team will participate in the Ladenburg Thalmann Virtual Healthcare Conference, held July 13-14, 2021.

Key Points: 
  • Apnimed, a clinical-stage pharmaceutical company focused on developing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that the Companys management team will participate in the Ladenburg Thalmann Virtual Healthcare Conference, held July 13-14, 2021.
  • Management will be available July 13th throughout the day for virtual one-on-one meetings.
  • Apnimeds lead development program targets the neurologic control of upper airway muscles to maintain an open airway during sleep.
  • Based in Cambridge, Mass., the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders.

New Data Presented at American Thoracic Society Meeting Reinforces the Potential of an Oral Drug Combination Therapy for the Treatment of Obstructive Sleep Apnea

Retrieved on: 
Monday, May 17, 2021
Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, Sleep disorders, Branches of biology, Sleep apnea, Physiology, Apnimed’s Investigational Programs, Obstructive Sleep Apnea, Apnimed, APNIMED’S INVESTIGATIONAL PROGRAMS, OBSTRUCTIVE SLEEP APNEA, APNIMED

We also look forward to data from our most advanced program, AD109, in the coming months.\xe2\x80\x9d\nThe data were presented in an oral mini-symposium held May 17, 2021, 3:30- 5:00 PM EDT.

Key Points: 
  • We also look forward to data from our most advanced program, AD109, in the coming months.\xe2\x80\x9d\nThe data were presented in an oral mini-symposium held May 17, 2021, 3:30- 5:00 PM EDT.
  • In this study presented at ATS, researchers evaluated the effect on OSA of reboxetine plus oxybutynin.
  • Further, the data highlight novel possibilities for pharmacotherapy to treat OSA.\n\xe2\x80\x9cResearchers have been exploring the potential of drug treatment options for the treatment of sleep apnea for years.
  • Based in Cambridge, Mass., the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders.

Apnimed Closes Series B Financing to Advance Once-Daily Oral Medication for Obstructive Sleep Apnea (OSA)

Retrieved on: 
Thursday, March 25, 2021
Professional services, Health, Medical devices, Other Health, Finance, Clinical trials, Pharmaceutical, Sleep disorders, Branches of biology, Sleep, Animal physiology, Sleep apnea, Obstructive sleep apnea, Apnea, Sleep surgery, AD109, Obstructive Sleep Apnea, Apnimed

The company is advancing its lead program, AD109, an oral disease-modifying therapeutic for the treatment of Obstructive Sleep Apnea (OSA), which is currently in late-stage Phase 2 clinical trials.

Key Points: 
  • The company is advancing its lead program, AD109, an oral disease-modifying therapeutic for the treatment of Obstructive Sleep Apnea (OSA), which is currently in late-stage Phase 2 clinical trials.
  • The vast majority of patients want a simple and convenient solution which a daily pill taken before sleep can offer.
  • People living with Obstructive Sleep Apnea need a safe, effective, and easy-to-use treatment option that addresses the underlying neurologic cause of the disease.
  • Based in Cambridge, Mass., the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders.